Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 17, 2010 | Supplemental Material + Accepted Version
Journal Article Open

Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses

Abstract

Foxp3^+ regulatory T (Treg) cells maintain immune homeostasis by limiting different types of inflammatory responses. Here, we report that miR-146a, one of the miRNAs prevalently expressed in Treg cells, is critical for their suppressor function. The deficiency of miR-146a in Treg cells resulted in a breakdown of immunological tolerance manifested in fatal IFNγ-dependent immune-mediated lesions in a variety of organs. This was likely due to augmented expression and activation of signal transducer and activator transcription 1 (Stat1), a direct target of miR-146a. Likewise, heightened Stat1 activation in Treg cells subjected to a selective ablation of SOCS1, a key negative regulator of Stat1 phosphorylation downstream of the IFNγ receptor, was associated with analogous Th1-mediated pathology. Our results suggest that specific aspects of Treg suppressor function are controlled by a single miRNA and that an optimal range of Stat1 activation is important for Treg-mediated control of Th1 responses and associated autoimmunity.

Additional Information

© 2010 Elsevier. Received 8 February 2010; revised 20 July 2010; accepted 7 August 2010. Published: September 16, 2010. Available online 16 September 2010. We thank A. Ramos for the help in key experiments, Y. Liang, P. Zarin, A. Bravo, and J. Herlihy for superb technical assistance, and all members of our laboratory for discussions. This work was supported by grants from the NIH (A.Y.R. and D.B.) and from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (A.Y.). L.-F.L. is a Leukemia and Lymphoma Society Fellow. A.C. is a Cancer Research Institute Fellow. A.Y.R. is a Howard Hughes Medical Institute investigator. D.B. is the director and M.P.B. and K.D.T. are employees of Regulus Therapeutics Inc., a company devoted to commercializing therapies directed at microRNAs.

Attached Files

Accepted Version - nihms-237728.pdf

Supplemental Material - f.mp3

Supplemental Material - mmc1.pdf

Files

mmc1.pdf
Files (9.6 MB)
Name Size Download all
md5:b1f22ccc85f647a752bfcb01ba2186a8
4.1 MB Preview Download
md5:6966e5a66e7a57d9b91e062e85e7cf35
2.6 MB Download
md5:a7389152e3e4a2d1025917c95ea0daac
3.0 MB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 20, 2023